Ischemic conditioning protects the rat retina in an experimental model of early type 2 diabetes

Experimental Neurology

Volumn 240, Issue 1, 2013, Pages 1-8

  Salido, Ezequiel M ^a   Dorfman, Damián ^a   Bordone, Melina ^a   Chianelli, Mónica S ^a   Sarmiento, María Inés Keller ^a   Aranda, Marcos ^a   Rosenstein, Ruth E ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Diabetic retinopathy; Experimental type 2 diabetes mellitus; Ischemic conditioning

Indexed keywords

CATALASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; INSULIN; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

A WAVE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B WAVE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; EYE PROTECTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; INSULIN TOLERANCE TEST; ISCHEMIC PRECONDITIONING; LIPID PEROXIDATION; MALE; METABOLIC DISORDER; MUELLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSCILLATORY POTENTIAL; PRIORITY JOURNAL; RAT; RETINA ISCHEMIA; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HUMANS; ISCHEMIA; ISCHEMIC PRECONDITIONING; MALE; RATS; RATS, WISTAR;

EID: 84870874089     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.11.006     Document Type: Article

References (40)

1. Aiello L.P., Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int. 2000, 77:S113-S119.
2. Belforte N.A., Moreno M.C., de Zavalía N., Sande P.H., Chianelli M.S., Keller Sarmiento M.I., Rosenstein R.E. Melatonin: a novel neuroprotectant for the treatment of glaucoma. J. Pineal Res. 2010, 48:353-364.
3. Biermann J., Lagrèze W.A., Schallner N., Schwer C.I., Goebel U. Inhalative preconditioning with hydrogen sulfide attenuated apoptosis after retinal ischemia/reperfusion injury. Mol. Vis. 2011, 17:1275-1286.
4. Bray G.A. Medical consequences of obesity. J. Clin. Endocrinol. Metab. 2004, 89:2583-2589.
5. Cunha-Vaz J., Bernardes R. Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. Prog. Retin. Eye Res. 2005, 24:355-377.
6. do Carmo A., Lopes C., Santos M., Proenca R., Cunha-Vaz J., Carvalho A.P. Nitric oxide synthase activity and l-arginine metabolism in the retinas from streptozotocin-induced diabetic rats. Gen. Pharmacol. 1998, 30:319-324.
7. Dreixler J.C., Barone F.C., Shaikh A.R., Du E., Roth S. Mitogen-activated protein kinase p38alpha and retinal ischemic preconditioning. Exp. Eye Res. 2009, 89:782-790.
8. Dreixler J.C., Hemmert J.W., Shenoy S.K., Shen Y., Lee H.T., Shaikh A.R., Rosenbaum D.M., Roth S. The role of Akt/protein kinase B subtypes in retinal ischemic preconditioning. Exp. Eye Res. 2009, 88:512-521.
9. El-Remessy A.B., Behzadian M.A., Abou-Mohamed G., Franklin T., Caldwell R.W., Caldwell R.B. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am. J. Pathol. 2003, 162:1995-2004.
10. Fernandez D.C., Bordone M.P., Chianelli M.S., Rosenstein R.E. Retinal neuroprotection against ischemia-reperfusion damage induced by postconditioning. Invest. Ophthalmol. Vis. Sci. 2009, 50:3922-3930.
11. Fernandez D.C., Sande P.H., Chianelli M.S., Aldana Marcos H.J., Rosenstein R.E. Induction of ischemic tolerance protects the retina from diabetic retinopathy. Am. J. Pathol. 2011, 178:2264-2274.
12. Fong D.S., Aiello L., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris F.L., Klein R., American Diabetes Association Retinopathy in diabetes. Diabetes Care 2004, 27:S84-S87.
13. Gidday J.M. Cerebral preconditioning and ischaemic tolerance. Nat. Rev. Neurosci. 2006, 7:437-448.
14. Goralski K.B., Sinal C.J. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter. Can. J. Physiol. Pharmacol. 2007, 85:113-132.
15. Hammes H.P., Federoff H.J., Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol. Med. 1995, 1:527-534.
16. Joussen A.M., Huang S., Poulaki V., Camphausen K., Beecken W.D., Kirchhof B., Adamis A.P. In vivo retinal gene expression in early diabetes. Invest. Ophthalmol. Vis. Sci. 2001, 42:3047-3057.
17. Joussen A.M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S.J., Rudge J., Yancopoulos G.D., Adamis A.P. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am. J. Pathol. 2002, 160:501-509.
18. Kaul K., Hodgkinson A., Tarr J.M., Kohner E.M., Chibber R. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?. Curr. Diabetes Rev. 2010, 6:294-303.
19. Korkmaz A., Ma S., Topal T., Rosales-Corral S., Tan D.X., Reiter R.J. Glucose: a vital toxin and potential utility of melatonin in protecting against the diabetic state. Mol. Cell. Endocrinol. 2012, 349:128-137.
20. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
21. Lutty G.A., McLeod D.S., Merges C., Diggs A., Plouét J. Localization of vascular endothelial growth factor in human retina and choroid. Arch. Ophthalmol. 1996, 114:971-977.
22. Matsuura T., Yamagishi S., Kodama Y., Shibata R., Ueda S., Narama I. Otsuka Long-Evan Tokushima Fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy. Int. J. Tissue React. 2005, 27:59-62.
23. Mokini Z., Marcovecchio M.L., Chiarelli F. Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. Diabetes Res. Clin. Pract. 2010, 87:313-321.
24. Moreno M.C., Campanelli J., Sande P., Sáenz D.A., Keller Sarmiento M.I., Rosenstein R.E. Retinal oxidative stress induced by high intraocular pressure. Free Radic. Biol. Med. 2004, 37:803-812.
25. Movassat J., Saulnier C., Portha B. Beta-cell mass depletion precedes the onset of hyperglycemia in the GK rat, a genetic model of non-insulin dependent diabetes mellitus. Diabetes Metab. 1995, 21:365-370.
26. Mühlhausler B.S. Nutritional models of type 2 diabetes mellitus. Methods Mol. Biol. 2009, 560:19-36.
27. Nicholson B.P., Schachat A.P. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:915-930.
28. Portha B., Blondel O., Serradas P., McEvoy R., Giroix M.H., Kergoat M., Bailbe D. The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabetes Metab. 1989, 15:61-75.
29. Roth S., Li B., Rosenbaum P.S., Gupta H., Goldstein I.M., Maxwell K.M., Gidday J.M. Preconditioning provides complete protection against retinal ischemic injury in rats. Invest. Ophthalmol. Vis. Sci. 1998, 39:777-785.
30. Roth S., Dreixler J.C., Shaikh A.R., Lee K.H., Bindokas V. Mitochondrial potassium ATP channels and retinal ischemic preconditioning. Invest. Ophthalmol. Vis. Sci. 2006, 47:2114-2124.
31. Salido E.M., de Zavalía N., Schreier L., De Laurentiis A., Rettori V., Chianelli M., Keller Sarmiento M.I., Arias P., Rosenstein R.E. Retinal changes in an experimental model of early type 2 diabetes in rats characterized by non-fasting hyperglycemia. Exp. Neurol. 2012, 236:151-160.
32. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87:4-14.
33. Stitt A.W., O'Neill C.L., O'Doherty M.T., Archer D.B., Gardiner T.A., Medina R.J. Vascular stem cells and ischaemic retinopathies. Prog. Retin. Eye Res. 2011, 30:149-166.
34. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am. J. Med. 2010, 123:S3-S11.
35. Surwit R.S., Kuhn C.M., Cochrane C., McCubbin J.A., Feinglos M.N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988, 37:1163-1167.
36. Tzekov R., Arden G.B. The electroretinogram in diabetic retinopathy. Surv. Ophthalmol. 1999, 44:53-60.
37. UK Prospective Diabetes Study (UKPDS) Group UKPDS 16: overview of 6years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
38. UK Prospective Diabetes Study (UKPDS) Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
39. Zheng L., Kern T.S. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front. Biosci. 2009, 14:3974-3987.
40. Zhu Y., Zhang Y., Ojwang B.A., Brantley M.A., Gidday J.M. Long-term tolerance to retinal ischemia by repetitive hypoxic preconditioning: role of HIF-1alpha and heme oxygenase-1. Invest. Ophthalmol. Vis. Sci. 2007, 48:1735-1743.